Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Hepion Pharmaceuticals ( (HEPA) ) just unveiled an announcement.
Hepion Pharmaceuticals announced the mutual termination of its merger agreement with Pharma Two B Ltd., initially entered into on July 19, 2024. The company also canceled a special meeting of stockholders and withdrew related proposals, reflecting a strategic pivot following its wind-down of the ASCEND-NASH clinical trial and ongoing efforts to preserve capital and explore value-maximizing strategies amid the current financial and NASH drug development landscape.
More about Hepion Pharmaceuticals
Hepion Pharmaceuticals, Inc., based in Edison, New Jersey, is a biopharmaceutical company previously focused on developing drug therapies for chronic liver diseases, including non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). The company targets fibrosis and inflammation, with rencofilstat being its primary cyclophilin inhibitor, aimed at addressing multiple pathologies related to liver disease progression.
YTD Price Performance: -80.56%
Average Trading Volume: 43,039
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $4.38M
For an in-depth examination of HEPA stock, go to TipRanks’ Stock Analysis page.
